Stockreport

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and Drug Administration (FDA) by year end Interim analysis requested by FDA demonstra [Read more]